170 related articles for article (PubMed ID: 19732452)
1. Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.
Pappano WN; Jung PM; Meulbroek JA; Wang YC; Hubbard RD; Zhang Q; Grudzien MM; Soni NB; Johnson EF; Sheppard GS; Donawho C; Buchanan FG; Davidsen SK; Bell RL; Wang J
BMC Cancer; 2009 Sep; 9():314. PubMed ID: 19732452
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
May CD; Landers SM; Bolshakov S; Ma X; Ingram DR; Kivlin CM; Watson KL; Sannaa GAA; Bhalla AD; Wang WL; Lazar AJ; Torres KE
Cancer Biol Ther; 2017 Oct; 18(10):816-826. PubMed ID: 29099264
[TBL] [Abstract][Full Text] [Related]
3. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Park JH; Choi YJ; Kim SY; Lee JE; Sung KJ; Park S; Kim WS; Song JS; Choi CM; Sung YH; Rho JK; Lee JC
Oncotarget; 2016 Apr; 7(16):22005-15. PubMed ID: 26980747
[TBL] [Abstract][Full Text] [Related]
4. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer.
Liu F; Liu Y; Liu X; Mao K; Zhong D; Marcus AI; Khuri FR; Sun SY; He Y; Zhou W
Lung Cancer; 2018 Sep; 123():36-43. PubMed ID: 30089593
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
Ohashi H; Adachi Y; Yamamoto H; Taniguchi H; Nosho K; Suzuki H; Arimura Y; Imai K; Carbone DP; Shinomura Y
Cancer Sci; 2012 Feb; 103(2):252-61. PubMed ID: 22044563
[TBL] [Abstract][Full Text] [Related]
7. Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity.
Lee HJ; Pham PC; Hyun SY; Baek B; Kim B; Kim Y; Min HY; Lee J; Lee HY
Mol Cancer; 2018 Feb; 17(1):50. PubMed ID: 29455661
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.
Sabbatini P; Rowand JL; Groy A; Korenchuk S; Liu Q; Atkins C; Dumble M; Yang J; Anderson K; Wilson BJ; Emmitte KA; Rabindran SK; Kumar R
Clin Cancer Res; 2009 May; 15(9):3058-67. PubMed ID: 19383820
[TBL] [Abstract][Full Text] [Related]
9. The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma.
Vaquero J; Lobe C; Tahraoui S; Clapéron A; Mergey M; Merabtene F; Wendum D; Coulouarn C; Housset C; Desbois-Mouthon C; Praz F; Fouassier L
Clin Cancer Res; 2018 Sep; 24(17):4282-4296. PubMed ID: 29716918
[No Abstract] [Full Text] [Related]
10. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors.
Nagle AM; Levine KM; Tasdemir N; Scott JA; Burlbaugh K; Kehm J; Katz TA; Boone DN; Jacobsen BM; Atkinson JM; Oesterreich S; Lee AV
Clin Cancer Res; 2018 Oct; 24(20):5165-5177. PubMed ID: 29941485
[No Abstract] [Full Text] [Related]
11. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
12. Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases.
Cassinelli G; Dal Bo L; Favini E; Cominetti D; Pozzi S; Tortoreto M; De Cesare M; Lecis D; Scanziani E; Minoli L; Naggi A; Vlodavsky I; Zaffaroni N; Lanzi C
Cancer Lett; 2018 Feb; 415():187-197. PubMed ID: 29225052
[TBL] [Abstract][Full Text] [Related]
13.
Panebianco F; Kelly LM; Liu P; Zhong S; Dacic S; Wang X; Singhi AD; Dhir R; Chiosea SI; Kuan SF; Bhargava R; Dabbs D; Trivedi S; Gandhi M; Diaz R; Wald AI; Carty SE; Ferris RL; Lee AV; Nikiforova MN; Nikiforov YE
Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2307-2312. PubMed ID: 28193878
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Lee Y; Wang Y; James M; Jeong JH; You M
Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
[TBL] [Abstract][Full Text] [Related]
15. The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels.
Alsina-Sanchis E; Figueras A; Lahiguera Á; Vidal A; Casanovas O; Graupera M; Villanueva A; Viñals F
Int J Cancer; 2016 Oct; 139(8):1894-903. PubMed ID: 27299695
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
Piao W; Wang Y; Adachi Y; Yamamoto H; Li R; Imsumran A; Li H; Maehata T; Ii M; Arimura Y; Lee CT; Shinomura Y; Carbone DP; Imai K
Mol Cancer Ther; 2008 Jun; 7(6):1483-93. PubMed ID: 18566219
[TBL] [Abstract][Full Text] [Related]
17. BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis.
Sanderson MP; Apgar J; Garin-Chesa P; Hofmann MH; Kessler D; Quant J; Savchenko A; Schaaf O; Treu M; Tye H; Zahn SK; Zoephel A; Haaksma E; Adolf GR; Kraut N
Mol Cancer Ther; 2015 Dec; 14(12):2762-72. PubMed ID: 26438154
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling.
Andersson MK; Afshari MK; Andrén Y; Wick MJ; Stenman G
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954282
[TBL] [Abstract][Full Text] [Related]
19. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
20. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
Qi W; Cooke LS; Stejskal A; Riley C; Croce KD; Saldanha JW; Bearss D; Mahadevan D
BMC Cancer; 2009 May; 9():142. PubMed ID: 19432987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
